Amgen (AMGN) | Stock Overview & Key Data
Amgen Performance Comparison
Stock Range
Today's Range
Low: $295.46
High: $300.50
on October 2, 2025
52 Week Range
Low: $253.30
High: $335.88
on December 19, 2024
on March 10, 2025
All-Time High: $346.85 on July 22, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$160.7B
EPS
12.27
P/E Ratio (TTM)
22.33
Forward P/E
13.25
P/B Ratio
19.85
PEG Ratio
0.24
Div. Yield
4.09%
ROE
99.14%
Beta
0.477
Debt to Equity
756.65
Financial Highlights
Profitability
Gross Margin
67.20%
Operating Margin
32.73%
Profit Margin
18.96%
Returns and Earnings
Return on Assets (TTM)
7.51%
Return on Equity (TTM)
99.14%
EBITDA
$15.9B
Net Income (TTM)
$6.6B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$65.02
Quarterly Revenue Growth (YoY)
9.40%
Quarterly Earnings Growth (YoY)
92.00%
Dividend Information
Last 12-Month Dividend
$11.64
Current Dividend Yield
4.09%
3-Year Average Dividend Yield
0.80%
3-Year Average Annual Dividend
$9.51
3-Year Total Dividends
$28.54
Ex-Dividend Date
August 22, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Amgen AMGN | 160.70B Large-cap | 9.67% | 3.65% | 0.19% | -2.72% | 14.70% | -6.96% | 29.85% | 25.64% |
| Eli Lilly and LLY | 658.23B Mega-cap | 14.73% | 11.52% | 5.21% | 0.20% | 5.37% | -7.59% | 150.98% | 422.60% |
| Johnson & Johnson JNJ | 437.40B Mega-cap | 4.64% | 4.45% | 19.56% | 19.71% | 29.13% | 16.03% | 16.09% | 23.19% |
| Pfizer PFE | 147.88B Large-cap | 14.75% | 8.41% | 6.95% | 9.64% | 1.77% | -5.25% | -36.01% | -22.43% |
| Gilead Sciences GILD | 139.74B Large-cap | -0.39% | -1.91% | -0.85% | -1.19% | 20.33% | 30.70% | 71.97% | 73.18% |
| Bristol-Myers Squibb BMY | 89.86B Large-cap | 5.34% | -3.54% | -3.99% | -23.27% | -19.48% | -15.25% | -34.39% | -26.03% |
Ownership & Short Interest
Insider Ownership
0.21%
Institutional Ownership
84.17%
Shares Short
13M
Short Ratio
6.63
Short % of Shares Outstanding
2.46%
Average 10-Day Volume
3M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is AMGN's 52-week high and low?
- In the last 52 weeks, Amgen reached a high of $335.88 (on March 10, 2025) and a low of $253.30 (on December 19, 2024).
- What is the market cap and P/E ratio for AMGN?
- Curious about Amgen's size and valuation? Its market capitalization stands at 160.70B. When it comes to valuation, the P/E ratio (trailing twelve months) is 22.33, and the forward P/E (looking ahead) is 13.25.
- Does AMGN pay dividends? If so, what's the yield?
- Yes, Amgen is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 4.09%, and the company has paid an average of $9.51 per share annually over the past 3 years.
- Who are Amgen's main competitors or similar companies to consider before investing?
When looking at Amgen, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY658.23B Healthcare Drug Manufacturers - General -7.59% 150.98% Johnson & Johnson
JNJ437.40B Healthcare Drug Manufacturers - General 16.03% 16.09% Pfizer
PFE147.88B Healthcare Drug Manufacturers - General -5.25% -36.01% Gilead Sciences
GILD139.74B Healthcare Drug Manufacturers - General 30.70% 71.97% Bristol-Myers Squibb
BMY89.86B Healthcare Drug Manufacturers - General -15.25% -34.39% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Amgen Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Amgen's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 99.14%, the Debt to Equity ratio from the most recent quarter is 756.65, and its Gross Profit Margin stands at 67.20%.
- What is the recent revenue and earnings growth for AMGN?
- Looking at Amgen's growth, its revenue over the trailing twelve months (TTM) was $35B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.40%, and quarterly earnings saw a YoY growth of 92.00%.
- How much of AMGN stock is held by insiders and institutions?
- Wondering who owns Amgen stock? Company insiders (like executives and directors) hold about 0.21% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 84.17%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.